Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
evorpacept + trastuzumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- ALX Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
rejuvenates the anti-tumor activity of innate immune cells by blocking CD47 to enhance phagocytosis. Trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 receptor, inhibiting the proliferation of HER2-overexpressing tumor cells. Paclitaxel is a cytotoxic small molecule that stabilizes microtubules, arresting cell division. This combination acts synergistically by combining immune checkpoint blockade (evorpacept), targeted inhibition of tumor growth (trastuzumab), and cytotoxic chemotherapy (paclitaxel). It is being developed primarily for gastric and gastroesophageal junction cancers after progression following prior anti-HER2 therapy, based on results from phase 2/3 ASPEN-06 clinical trial, where it has shown improved overall response rates and duration of response compared to control arms[1][2][3][4].
- Other names
- evorpacept + trastuzumab + paclitaxelALX148 + trastuzumab + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD47 (Cluster of Differentiation 47)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on evorpacept + trastuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on evorpacept + trastuzumab + paclitaxel.